Loading data for ATTO — first visit, this takes a few seconds.

Attovia Therapeutics, Inc. (ATTO)

NasdaqGM: ATTO · Real-Time Price · USD

22.79

+0.26 (1.15%)

At close: Sep 11, 2026, 8:00 PM

22.79

+0.00%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	n/a
Market Cap	1.04B
Revenue (ttm)	1.8M
Net Income (ttm)	-70.1M
	0.00
	-1.63
	n/a
	-9.58
P/B (ttm)	-0.71
P/S (ttm)	578.00
Earnings Date	Nov 11, 2026

Ask	n/a
Volume	175,769
Avg. Volume (20D)	425,555
Open	22.43
Previous Close	22.53
Day's Range	22.00 - 24.01
52-Week Range	16.15 - 28.00
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ATTO

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 5, 2026

Employees 44

Stock Exchange NasdaqGM

Ticker Symbol ATTO

Website https://www.attovia.com

Full Company Profile

Financial Performance

In 2025, Attovia Therapeutics's revenue was 1.35M, an increase of undefined% compared to the previous year's 0. Earnings were -60.63M, an increase of 52.33%.

Financial Statements

Earnings Surprise

Attovia Therapeutics has released their quarterly earnings on Sep 2, 2026:

Revenue of $450K misses estimates by $0, with Infinity% YoY growth.
EPS of -4.88 misses estimates by -0.27, with -Infinity% YoY decline.

Next Earnings Release

Attovia Therapeutics, Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 week ago · MT Newswires

Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says

Attovia Therapeutics' (ATTO) ATTOBODY platform should position the company as a key player in immuno

1 week ago · The Fly

Deere upgraded, Lumentum initiated: Wall Street's top analyst calls

1 week ago · 24/7 Wall St.

Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More

Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that cou...

2 weeks ago · Trefis

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

2 weeks ago · Trefis

Moderna Stock Had A Readout Waiting In Plain Sight

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

Page 1 of 2

Attovia Therapeutics, Inc. (ATTO)